SCHEMBL2322693

SCHEMBL2322693

Nc1ccc(-c2cc(F)cc(F)c2)nc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LDHA P00338 2/20 0.55
KDM1A O60341 4/20 0.48
MAP4K4 O95819 3/20 0.44
HPGDS O60760 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
PIK3CA P42336 1/20 0.37
NPC1 O15118 2/20 0.36
TP53 P04637 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MET P08581 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16826203 0.83 CYP11B1 (0.44) LDHAKDM1AMAP4K4HPGDSKDM4E
SCHEMBL2318238 0.83 HPGDS (0.60) LDHAMAP4K4HPGDSKDM4EMEN1
SCHEMBL30436719 0.82 NPC1 (0.53) LDHAKDM1AKDM4EMEN1KMT2A
SCHEMBL3173634 0.82 NPC1 (0.53) LDHAKDM1AKDM4EMEN1KMT2A
SCHEMBL19072737 0.81 GRM5 (0.47) LDHAKDM1AHPGDSNPC1RXFP1
SCHEMBL8974216 0.78 METAP2 (0.45) KDM1AKDM4EMEN1KMT2ANPC1
SCHEMBL30337692 0.78 METAP2 (0.45) KDM1AKDM4EMEN1KMT2ANPC1
SCHEMBL14988156 0.78 KDM1A (0.44) LDHAKDM1AKDM4ESMN1; SMN2
SCHEMBL6804411 0.76 METAP2 (0.48) KDM1AKDM4EMEN1KMT2ATAAR1
SCHEMBL30087143 0.76 METAP2 (0.48) KDM1AKDM4EMEN1KMT2ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230497-A1 BIOLOGICALLY ACTIVE AMIDES H. LUNDBECK A/S (DK) 2011-09-22 US disclosed
EP-2352730-A2 BIOLOGICALLY ACTIVE AMIDES H. Lundbeck A/S (DK) 2011-08-10 EP disclosed
WO-2010053861-A2 BIOLOGICALLY ACTIVE AMIDES H. LUNDBECK A/S (DK) 2010-05-14 WO disclosed
EP-1343503-B1 HETEROARYL UREA NEUROPEPTIDE Y Y5 RECEPTOR ANTAGONISTS SCHERING CORP (US) 2008-11-12 EP disclosed
US-7309704-B2 Heteroaryl urea neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-12-18 US disclosed
US-7309704-B2 Heteroaryl urea neuropeptide Y Y5 receptor antagonists SCHERING CORPORATION (US) 2007-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230497-A1 BIOLOGICALLY ACTIVE AMIDES NPY5R, NPY1R, NPY2R LDHA 3016/4885KDM1A 3077/4885MAP4K4 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.